These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

699 related items for PubMed ID: 14985447

  • 1. Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    Hayley S, Crocker SJ, Smith PD, Shree T, Jackson-Lewis V, Przedborski S, Mount M, Slack R, Anisman H, Park DS.
    J Neurosci; 2004 Feb 25; 24(8):2045-53. PubMed ID: 14985447
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson's disease.
    Wang Y, Zhang Y, Wei Z, Li H, Zhou H, Zhang Z, Zhang Z.
    J Neurol Sci; 2009 Oct 15; 285(1-2):172-7. PubMed ID: 19604516
    [Abstract] [Full Text] [Related]

  • 4. Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease.
    Ghosh A, Roy A, Matras J, Brahmachari S, Gendelman HE, Pahan K.
    J Neurosci; 2009 Oct 28; 29(43):13543-56. PubMed ID: 19864567
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
    Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC.
    J Neurochem; 2002 Aug 28; 82(3):615-24. PubMed ID: 12153485
    [Abstract] [Full Text] [Related]

  • 7. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
    Tristão FS, Lazzarini M, Martin S, Amar M, Stühmer W, Kirchhoff F, Gomes LA, Lanfumey L, Prediger RD, Sepulveda JE, Del-Bel EA, Raisman-Vozari R.
    Neurotox Res; 2016 Apr 28; 29(3):364-80. PubMed ID: 26403659
    [Abstract] [Full Text] [Related]

  • 8. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
    Saporito MS, Brown EM, Miller MS, Carswell S.
    J Pharmacol Exp Ther; 1999 Feb 28; 288(2):421-7. PubMed ID: 9918541
    [Abstract] [Full Text] [Related]

  • 9. Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice.
    Bolin LM, Strycharska-Orczyk I, Murray R, Langston JW, Di Monte D.
    J Neurochem; 2002 Oct 28; 83(1):167-75. PubMed ID: 12358740
    [Abstract] [Full Text] [Related]

  • 10. Attenuation of MPTP-induced neurotoxicity and locomotor dysfunction in Nucling-deficient mice via suppression of the apoptosome pathway.
    Teng X, Sakai T, Liu L, Sakai R, Kaji R, Fukui K.
    J Neurochem; 2006 May 28; 97(4):1126-35. PubMed ID: 16686692
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
    Liu LX, Chen WF, Xie JX, Wong MS.
    Neurosci Res; 2008 Feb 28; 60(2):156-61. PubMed ID: 18054104
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Activation of the c-Jun N terminal kinase pathway in an animal model of Parkinson's disease.
    Willesen MG, Gammeltoft S, Vaudano E.
    Ann N Y Acad Sci; 2002 Nov 28; 973():237-40. PubMed ID: 12485868
    [Abstract] [Full Text] [Related]

  • 15. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice.
    Ohashi S, Mori A, Kurihara N, Mitsumoto Y, Nakai M.
    Neurosci Lett; 2006 Jun 19; 401(1-2):183-7. PubMed ID: 16581184
    [Abstract] [Full Text] [Related]

  • 16. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Sawada H, Hishida R, Hirata Y, Ono K, Suzuki H, Muramatsu S, Nakano I, Nagatsu T, Sawada M.
    J Neurosci Res; 2007 Jun 19; 85(8):1752-61. PubMed ID: 17469135
    [Abstract] [Full Text] [Related]

  • 17. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation.
    Moon M, Kim HG, Hwang L, Seo JH, Kim S, Hwang S, Kim S, Lee D, Chung H, Oh MS, Lee KT, Park S.
    Neurotox Res; 2009 May 19; 15(4):332-47. PubMed ID: 19384567
    [Abstract] [Full Text] [Related]

  • 18. Exacerbation of dopaminergic terminal damage in a mouse model of Parkinson's disease by the G-protein-coupled receptor protease-activated receptor 1.
    Hamill CE, Caudle WM, Richardson JR, Yuan H, Pennell KD, Greene JG, Miller GW, Traynelis SF.
    Mol Pharmacol; 2007 Sep 19; 72(3):653-64. PubMed ID: 17596374
    [Abstract] [Full Text] [Related]

  • 19. Loss of collapsin response mediator protein 4 suppresses dopaminergic neuron death in an 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
    Tonouchi A, Nagai J, Togashi K, Goshima Y, Ohshima T.
    J Neurochem; 2016 Jun 19; 137(5):795-805. PubMed ID: 26991935
    [Abstract] [Full Text] [Related]

  • 20. Pain perception in acute model mice of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Park J, Lim CS, Seo H, Park CA, Zhuo M, Kaang BK, Lee K.
    Mol Pain; 2015 May 17; 11():28. PubMed ID: 25981600
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.